Low-dose ruxolitinib shows effective in treating myelofibrosis
The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West Ch...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2021, Vol.100 (1), p.135-141 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 1 |
| container_start_page | 135 |
| container_title | Annals of hematology |
| container_volume | 100 |
| creator | Yang, Yunfan Luo, Hongmei Zheng, Yuhuan Zou, Zhongqing Niu, Ting Jia, Yongqian Zhu, Huanling Liu, Ting Wu, Yu Chang, Hong Ji, Jie Li, Jian Pan, Ling |
| description | The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West China Hospital, Sichuan University, China. A total of 44 MPN-MF patients received a low dose of ruxolitinib (daily dose ≤ 10 mg), while another 44 patients received 10–25 mg twice daily. Low-dose ruxolitinib treatment resulted in slow, but gradual spleen response. Compared with baseline, the mean changes in palpable spleen length in the low- and high-dose groups were −26.9 and −49.0% after 12 weeks of treatment, respectively, and −46.7 and −64.1% after 48 weeks of treatment, respectively. In the low dose group, the median myeloproliferative neoplasm symptom assessment form (MPN-SAF) total symptom score (TSS) decreased by 37.8 and 35.9% at the 12 weeks and 48 weeks after treatment, respectively. No statistical difference was observed in MPN-SAF TSS among different dose groups. After 48 weeks of treatment, bone marrow (BM) fibrosis improved in 43.3% (13/30) of evaluated patients and was stable in 56.7% (17/30) patients. In the low-dose treated group, BM fibrosis improved in 50% patients and was stable in remaining 50%. Low-dose ruxolitinib is effective in treating MF. |
| doi_str_mv | 10.1007/s00277-020-04311-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2475029919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475029919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7a3553d6096d18192f624aa4e9d036099bf15d1a3043f1ceb4f50b625295200e3</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYuPjD3BAlTgHnK-2uSChiS9pEhc4R2mbjExbM5KWsf16Ah1wwxdL9uvX9oPQGYFLAlBcRQBaFBgoYOCMELzdQ2PCGcUgSr6PxiCZxCLFCB3FOAcgtOT0EI0Yg5KVORuj66lf48ZHk4X-wy9c51pXZfHVr2NmrDV1595N5tqsC0an5ixbbszCW1cFH108QQdWL6I53eVj9HJ3-zx5wNOn-8fJzRTXrBAdLjQTgjU5yLwhJZHU5pRrzY1sgKWqrCwRDdEs_WFJbSpuBVQ5FVQKCmDYMboYfFfBv_Umdmru-9CmlYryQgCVksikooOqTsfFYKxaBbfUYaMIqC9kakCmEjL1jUxt09D5zrqvlqb5HflhlARsEMTUamcm_O3-x_YTh4B2Nw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475029919</pqid></control><display><type>article</type><title>Low-dose ruxolitinib shows effective in treating myelofibrosis</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Yang, Yunfan ; Luo, Hongmei ; Zheng, Yuhuan ; Zou, Zhongqing ; Niu, Ting ; Jia, Yongqian ; Zhu, Huanling ; Liu, Ting ; Wu, Yu ; Chang, Hong ; Ji, Jie ; Li, Jian ; Pan, Ling</creator><creatorcontrib>Yang, Yunfan ; Luo, Hongmei ; Zheng, Yuhuan ; Zou, Zhongqing ; Niu, Ting ; Jia, Yongqian ; Zhu, Huanling ; Liu, Ting ; Wu, Yu ; Chang, Hong ; Ji, Jie ; Li, Jian ; Pan, Ling</creatorcontrib><description>The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West China Hospital, Sichuan University, China. A total of 44 MPN-MF patients received a low dose of ruxolitinib (daily dose ≤ 10 mg), while another 44 patients received 10–25 mg twice daily. Low-dose ruxolitinib treatment resulted in slow, but gradual spleen response. Compared with baseline, the mean changes in palpable spleen length in the low- and high-dose groups were −26.9 and −49.0% after 12 weeks of treatment, respectively, and −46.7 and −64.1% after 48 weeks of treatment, respectively. In the low dose group, the median myeloproliferative neoplasm symptom assessment form (MPN-SAF) total symptom score (TSS) decreased by 37.8 and 35.9% at the 12 weeks and 48 weeks after treatment, respectively. No statistical difference was observed in MPN-SAF TSS among different dose groups. After 48 weeks of treatment, bone marrow (BM) fibrosis improved in 43.3% (13/30) of evaluated patients and was stable in 56.7% (17/30) patients. In the low-dose treated group, BM fibrosis improved in 50% patients and was stable in remaining 50%. Low-dose ruxolitinib is effective in treating MF.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04311-z</identifier><identifier>PMID: 33083863</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Dose-Response Relationship, Drug ; Female ; Hematology ; Humans ; Inhibitor drugs ; Janus Kinase Inhibitors - administration & dosage ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - pathology ; Pyrazoles - administration & dosage ; Retrospective Studies ; Spleen - drug effects ; Spleen - pathology ; Treatment Outcome ; Tumors</subject><ispartof>Annals of hematology, 2021, Vol.100 (1), p.135-141</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7a3553d6096d18192f624aa4e9d036099bf15d1a3043f1ceb4f50b625295200e3</citedby><cites>FETCH-LOGICAL-c375t-7a3553d6096d18192f624aa4e9d036099bf15d1a3043f1ceb4f50b625295200e3</cites><orcidid>0000-0003-0650-7585</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04311-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04311-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33083863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Yunfan</creatorcontrib><creatorcontrib>Luo, Hongmei</creatorcontrib><creatorcontrib>Zheng, Yuhuan</creatorcontrib><creatorcontrib>Zou, Zhongqing</creatorcontrib><creatorcontrib>Niu, Ting</creatorcontrib><creatorcontrib>Jia, Yongqian</creatorcontrib><creatorcontrib>Zhu, Huanling</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Wu, Yu</creatorcontrib><creatorcontrib>Chang, Hong</creatorcontrib><creatorcontrib>Ji, Jie</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Pan, Ling</creatorcontrib><title>Low-dose ruxolitinib shows effective in treating myelofibrosis</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West China Hospital, Sichuan University, China. A total of 44 MPN-MF patients received a low dose of ruxolitinib (daily dose ≤ 10 mg), while another 44 patients received 10–25 mg twice daily. Low-dose ruxolitinib treatment resulted in slow, but gradual spleen response. Compared with baseline, the mean changes in palpable spleen length in the low- and high-dose groups were −26.9 and −49.0% after 12 weeks of treatment, respectively, and −46.7 and −64.1% after 48 weeks of treatment, respectively. In the low dose group, the median myeloproliferative neoplasm symptom assessment form (MPN-SAF) total symptom score (TSS) decreased by 37.8 and 35.9% at the 12 weeks and 48 weeks after treatment, respectively. No statistical difference was observed in MPN-SAF TSS among different dose groups. After 48 weeks of treatment, bone marrow (BM) fibrosis improved in 43.3% (13/30) of evaluated patients and was stable in 56.7% (17/30) patients. In the low-dose treated group, BM fibrosis improved in 50% patients and was stable in remaining 50%. Low-dose ruxolitinib is effective in treating MF.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Janus Kinase Inhibitors - administration & dosage</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Pyrazoles - administration & dosage</subject><subject>Retrospective Studies</subject><subject>Spleen - drug effects</subject><subject>Spleen - pathology</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1PwzAMhiMEYuPjD3BAlTgHnK-2uSChiS9pEhc4R2mbjExbM5KWsf16Ah1wwxdL9uvX9oPQGYFLAlBcRQBaFBgoYOCMELzdQ2PCGcUgSr6PxiCZxCLFCB3FOAcgtOT0EI0Yg5KVORuj66lf48ZHk4X-wy9c51pXZfHVr2NmrDV1595N5tqsC0an5ixbbszCW1cFH108QQdWL6I53eVj9HJ3-zx5wNOn-8fJzRTXrBAdLjQTgjU5yLwhJZHU5pRrzY1sgKWqrCwRDdEs_WFJbSpuBVQ5FVQKCmDYMboYfFfBv_Umdmru-9CmlYryQgCVksikooOqTsfFYKxaBbfUYaMIqC9kakCmEjL1jUxt09D5zrqvlqb5HflhlARsEMTUamcm_O3-x_YTh4B2Nw</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Yang, Yunfan</creator><creator>Luo, Hongmei</creator><creator>Zheng, Yuhuan</creator><creator>Zou, Zhongqing</creator><creator>Niu, Ting</creator><creator>Jia, Yongqian</creator><creator>Zhu, Huanling</creator><creator>Liu, Ting</creator><creator>Wu, Yu</creator><creator>Chang, Hong</creator><creator>Ji, Jie</creator><creator>Li, Jian</creator><creator>Pan, Ling</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0003-0650-7585</orcidid></search><sort><creationdate>2021</creationdate><title>Low-dose ruxolitinib shows effective in treating myelofibrosis</title><author>Yang, Yunfan ; Luo, Hongmei ; Zheng, Yuhuan ; Zou, Zhongqing ; Niu, Ting ; Jia, Yongqian ; Zhu, Huanling ; Liu, Ting ; Wu, Yu ; Chang, Hong ; Ji, Jie ; Li, Jian ; Pan, Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7a3553d6096d18192f624aa4e9d036099bf15d1a3043f1ceb4f50b625295200e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Janus Kinase Inhibitors - administration & dosage</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Pyrazoles - administration & dosage</topic><topic>Retrospective Studies</topic><topic>Spleen - drug effects</topic><topic>Spleen - pathology</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Yunfan</creatorcontrib><creatorcontrib>Luo, Hongmei</creatorcontrib><creatorcontrib>Zheng, Yuhuan</creatorcontrib><creatorcontrib>Zou, Zhongqing</creatorcontrib><creatorcontrib>Niu, Ting</creatorcontrib><creatorcontrib>Jia, Yongqian</creatorcontrib><creatorcontrib>Zhu, Huanling</creatorcontrib><creatorcontrib>Liu, Ting</creatorcontrib><creatorcontrib>Wu, Yu</creatorcontrib><creatorcontrib>Chang, Hong</creatorcontrib><creatorcontrib>Ji, Jie</creatorcontrib><creatorcontrib>Li, Jian</creatorcontrib><creatorcontrib>Pan, Ling</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Yunfan</au><au>Luo, Hongmei</au><au>Zheng, Yuhuan</au><au>Zou, Zhongqing</au><au>Niu, Ting</au><au>Jia, Yongqian</au><au>Zhu, Huanling</au><au>Liu, Ting</au><au>Wu, Yu</au><au>Chang, Hong</au><au>Ji, Jie</au><au>Li, Jian</au><au>Pan, Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose ruxolitinib shows effective in treating myelofibrosis</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2021</date><risdate>2021</risdate><volume>100</volume><issue>1</issue><spage>135</spage><epage>141</epage><pages>135-141</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>The aim of this study was to investigate the effect of low-dose ruxolitinib (daily dose ≤ 10 mg) for the treatment of myelofibrosis (MF). A retrospective analysis was performed on a total of 88 patients with myeloproliferative neoplasm-associated MF (MPN-MF) who were diagnosed and treated in West China Hospital, Sichuan University, China. A total of 44 MPN-MF patients received a low dose of ruxolitinib (daily dose ≤ 10 mg), while another 44 patients received 10–25 mg twice daily. Low-dose ruxolitinib treatment resulted in slow, but gradual spleen response. Compared with baseline, the mean changes in palpable spleen length in the low- and high-dose groups were −26.9 and −49.0% after 12 weeks of treatment, respectively, and −46.7 and −64.1% after 48 weeks of treatment, respectively. In the low dose group, the median myeloproliferative neoplasm symptom assessment form (MPN-SAF) total symptom score (TSS) decreased by 37.8 and 35.9% at the 12 weeks and 48 weeks after treatment, respectively. No statistical difference was observed in MPN-SAF TSS among different dose groups. After 48 weeks of treatment, bone marrow (BM) fibrosis improved in 43.3% (13/30) of evaluated patients and was stable in 56.7% (17/30) patients. In the low-dose treated group, BM fibrosis improved in 50% patients and was stable in remaining 50%. Low-dose ruxolitinib is effective in treating MF.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33083863</pmid><doi>10.1007/s00277-020-04311-z</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0650-7585</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2021, Vol.100 (1), p.135-141 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_journals_2475029919 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Dose-Response Relationship, Drug Female Hematology Humans Inhibitor drugs Janus Kinase Inhibitors - administration & dosage Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Primary Myelofibrosis - drug therapy Primary Myelofibrosis - pathology Pyrazoles - administration & dosage Retrospective Studies Spleen - drug effects Spleen - pathology Treatment Outcome Tumors |
| title | Low-dose ruxolitinib shows effective in treating myelofibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A20%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20ruxolitinib%20shows%20effective%20in%20treating%20myelofibrosis&rft.jtitle=Annals%20of%20hematology&rft.au=Yang,%20Yunfan&rft.date=2021&rft.volume=100&rft.issue=1&rft.spage=135&rft.epage=141&rft.pages=135-141&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04311-z&rft_dat=%3Cproquest_cross%3E2475029919%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475029919&rft_id=info:pmid/33083863&rfr_iscdi=true |